cis-Tranilast NEW
| Price | Get Latest Price | ||
| Package | 5mg | 20mg | 50mg |
| Min. Order: | 1mg |
| Supply Ability: | 10000 |
| Update Time: | 2025-05-07 |
Product Details
| Product Name: cis-Tranilast | CAS No.: 91920-58-0 |
| Min. Order: 1mg | Purity: >95% HPLC |
| Supply Ability: 10000 | Release date: 2025/05/07 |
| Molecular Formula:: C18H17NO5 | Molecular Weight:: 327.33 |
| Appearance: Pale yellow soild | Storage: 2-8°C Refrigerator |
| Product Catalog： | T097001 |
| CAS No.： | 91920-58-0 |
| Product Name： | cis-Tranilast |
| Purity： | >95% HPLC |
| Synonyms: | (Z)-2-(3-(3,4-dimethoxyphenyl)acrylamido)benzoic acid |
| Molecular Formula: | C18H17NO5 |
| Mol. Weight： | 327.33 |
| Appearance: | Pale yellow soild |
| Storage： | 2-8°C Refrigerator |
| Contact: | WhatsAPP: +86 17320513646 E-mail: anna@molcoo.com |
| Note: | We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS. This product is intended for laboratory use only! |
| Background: | Cis - tranilast is the cis - isomer of tranilast. Tranilast, a drug developed by Kissei Pharmaceutical Co., Ltd. (Japan) in 1982, is an anti - allergic agent used for the prevention and treatment of diseases such as allergic rhinitis, allergic asthma, and atopic dermatitis. However, the cinnamamide group in the structure of tranilast is photounstable and can be converted into cis - isomer and dimer forms when exposed to light, resulting in a decrease in bioavailability. Cis - tranilast is one of the photoisomerization products of tranilast, and its formation affects the stability and efficacy of tranilast. |
Company Profile Introduction
1. Drug standards and drug impurity reference substances: provide more than 20,000 kinds of spot impurity reference substances, with sufficient supply and same-day delivery. We have a professional R&D team and comprehensive quality control testing to ensure product quality and reliability.
2. Customized synthesis of impurities and new molecules: Quickly respond to the customized needs of CDE impurities, stably supply impurities that have established quality standards, and provide customized synthesis services for new compounds in the research and development of innovative drugs.
3. Preparation and separation of unknown impurities: With a professional impurity preparation and separation technical team and SFC preparation and separation instruments, we can solve the problems of impurity preparation in complex projects.
4. Process development of new drug intermediates: provide the supply of new drugs and new molecular impurities, process optimization services, as well as the screening and impurity analysis of commercialization routes.
5. Peptide synthesis: Provide customized peptide synthesis services, and cover all kinds of degradation impurities and process impurities generated in the research and development of peptide drugs. At the same time, it provides comprehensive structural confirmation data and customized testing services.
You may like
China
INQUIRY